Pneumocystis carinii pneumonia in adult non-HIV disorders

Journal of Intensive Care Medicine

Volumn 17, Issue 6, 2002, Pages 283-301

  Gilmartin, Geoffrey S ^a   Koziel, Henry ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Mechanical ventilation; Pneumocystis carinii; Pneumonia; Respiratory failure

Indexed keywords

ANTIINFECTIVE AGENT; CORTICOSTEROID;

ARTIFICIAL VENTILATION; ASSISTED VENTILATION; BRONCHOSCOPY; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE COURSE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INFECTION RISK; INTENSIVE CARE UNIT; INTUBATION; LUNG INFILTRATE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; REVIEW;

EID: 33748425267     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066602238031     Document Type: Review

References (208)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
2. Mansharamani N, Garland R, Delaney D, Koziel H. Management and outcome patterns for adult Pneumocystis carinii pneumonia 1985-95: comparison of HIV-associated cases to other immunocompromised states. Chest. 2000;118:704-711.
3. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest. 1998;113:1215-1224.
4. Jacobs J, Libby D, Winters R, et al. A cluster of Pneumocystis carinii pneumonia in adults without predisposing illnesses. N Engl J Med. 1991;324:246-250.
5. Palanage P, Serra P, Di Sabato F, Contini C, Giacovazzo M. Pneumocystis carinii pneumonia in a patient with chronic obstructive pulmonary disease but no evident immunoincompetence. Clin Infect Dis. 1994;19:543-544.
6. Ognibene FP, Shelhamer JH, Hoffman GS, et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med. 1995;151:795-799.
7. Godeau B, Coutant-Perronne V, Le Thi Huong D, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol. 1994;21:246-251.
8. Rosen P, Armstrong D, Ramos C. Pneumocystis carinii pneumonia: a clinicopathologic study of twenty patients with neoplastic diseases. Am J Med. 1972;53:428-436.
9. Varthalitis I, Aoun M, Daneau D, Meunier F. Pneumocystis carinii pneumonia in patients with cancer: an increasing incidence. Cancer 1993;71:481-485.
10. Peters SG, Prakash UBS. Pneumocystis carinii pneumonia: review of 53 cases. Am J Med. 1987;82:73-78.
11. Arend SM, Kroon FP, Van't Wout JW. Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993: an analysis of 78 cases. Arch Intern Med. 1995;155:2436-2441.
12. Koziel H. Pneumocystis carinii. In: Calderone RA, Cihlar RL, eds. Fungal Pathogenesis. New York, NY: Marcel Dekker Inc; 2002:227-260.
13. Ruffolo J, Cushion M, Walzer P. Microscopic techniques for studying Pneumocystis carinii in fresh specimens. J Clin Microbiol. 1986;23:17-21.
14. Cushion M, Stringer J, Walzer P. Cellular and molecular biology of Pneumocystis carinii. Int Rev Cytol. 1991;131:59-107.
15. Narasimhan S, Armstrong MYK, McClung JK, Richards FF, Spicer EK. Prohibitin, a putative negative control element present in Pneumocystis carinii. Infect Immun. 1997;65:5125-5130.
16. Cushion M, DeStefano J, Walzer P. Pneumocystis carinii: surface reactive carbohydrates detected by lectin probes. Exp Parasitol. 1988;67:137-147.
17. Yoshikawa H, Tegoshi T, Yoshida Y. Detection of surface carbohydrates on Pneumocystis carinii by fluorescein-conjugated lectins. Parasitol Res. 1987;74:43-49.
18. Yoshikawa H, Morioka H, Yoshida Y. Ultrastructural detection of carbohydrates in the pellicle of Pneumocystis carinii. Parasitol Res. 1988;74:537-543.
19. Kaneshiro ES, Cushion MT, Walzer PD, Jayasimhulu K. Analysis of Pneumocystis fatty acids. J Protozool. 1989;36:69S-72S.
20. Furlong ST, Samia JA, Rose RM, Fishman JA. Phytosterols are present in Pneumocystis carinii. Antimicrob Agents Chemother. 1994;38:2534-2540.
21. Stringer S, Stringer J, Blase M, Walzer P, Cushion M. Pneumocystis carinii: sequence from ribosomal RNA implies a close relationship with fungi. Exp Parasitol. 1989;68:450-461.
22. Edman JC, Kovacs JA, Mansur H, Santi DV, Elwood HJ, Sogin ML. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature. 1988;334:519-522.
23. Pixley F, Wakefield A, Banerji S, Hopkin J. Mitochondrial gene sequences show fungal homology for Pneumocystis carinii. Mol Microbiol. 1991;5:1347-1351.
24. Ypma-Wong MF, Fonzi WA, Sypherd PS. Fungus-specific translation elongation factor 3 gene present in Pneumocystis carinii. Infect Immun. 1992;60:4140-4145.
25. Edman J, Edman U, Cao M, Lundgren B, Kovacs J, Santi D. Isolation and expression of the Pneumocystis carinii dihydrofolate reductase gene. Proc Natl Acad Sci U S A. 1989;86:8625.
26. Edman U, Edman J, Lundgren B, Santi D. Isolation and expression of Pneumocystis carinii thymidylate synthase gene. Proc Natl Acad Sci U S A. 1989;86:6503.
27. Mei Q, Turner RE, Sorial V, Klivington D, Angus CW, Kovacs JA. Characterization of major glycoprotein genes of human Pneumocystis carinii and high-level expression of a conserved region. Infect Immun. 1998;66:4268-4273.
28. Sumulian AG, Sullivan DW, Linke MJ, et al. Geographic variation in the humoral response to Pneumocystis carinii. J Infect Dis. 1990;167:1243-1247.
29. Wakefield AE, Stewart TJ, Moxon ER, et al. Infection with Pneumocystis carinii is prevalent in healthy Gambian children. Trans Roy Soc Trop Med Hyg. 1990;84:800-802.
30. Pifer L, Hughes W, Stagno S, Woods D. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics. 1978;62:35-41.
31. Meuwissen J, Tauber I, Leewenberg A, Beckers P, Shiehen J. Parasitologic and serologic observations of infection with Pneumocystis in humans. J Infect Dis. 1977;136:43-49.
32. Peglow S, Smulian G, Linke M, et al. Serologic responses to specific Pneumocystis carinii antigens in health and disease. J Infect Dis. 1990;161:296-306.
33. Hughes W. Natural mode of acquisition for de novo infection with Pneumocystis carinii. J Infect Dis. 1982;145:842-848.
34. Soulez B, Palluault F, Cesbron J, Dei-Cas E, Carpon A, Camus D. Introduction of Pneumocystis carinii in a colony of SCID mice. J Protozool. 1991;38:123S-125S.
35. Chusid M, Heyrman K. An outbreak of Pneumocystis carinii at a pediatric hospital. Pediatrics. 1978;62:1031-1035.
36. Singer C, Armstrong D, Rosen P, Schottenfeld D. Pneumocystis carinii pneumonia: a cluster of eleven cases. Ann Intern Med. 1975;82:772-777.
37. Hughes WT. Geographic distribution. In: Hughes WT, ed. Pneumocystis carinii Pneumonitis. Boca Raton, Fla: CRC Press Inc; 1987:33-56.
38. Hoover DR, Graham NMH, Bacellar H, et al. Epidemiologic patterns of upper respiratory illnesses and Pneumocystis carinii pneumonia in homosexual men. Am Rev Respir Dis. 1991;143:756-759.
39. Delmas MC, Schwoebel V, Heisterkamp SH, Downs AM, Ancelle-Park RA, Brunet JB. Recent trends in Pneumocystis carinii pneumonia as AIDS-defining disease in nine European countries. J AIDS. 1995;9:74-80.
40. Walzer PD, Perl DP, Krogstead DJ, Rawson PG, Schultz MG. Pneumocystis carinii pneumonia in the United States: epidemiologic, diagnostic, and clinical features. Ann Intern Med. 1974;80:83-93.
41. Wakefield AE. Detection of DNA sequences identical to Pneumocystis carinii in samples of ambient air. J Euk Microbiol. 1994;41:116S.
42. Wakefield AE. DNA sequences identical to Pneumocystis carinii f. sp. carinii and Pneumocystis carinii f. sp. hominus in samples of air spore. J Clin Microbiol. 1996;34:1754-1759.
43. Bartlett MS, Lu JJ, Lee CH, Durant PJ, Queener SF, Smith JW. Types of Pneumocystis carinii detected in air samples. J Euk Microbiol. 1996;43:44S.
44. Hughes W. Natural occurrences in animals. In: Hughes WT, ed. Pneumocystis carinii Pneumonitis. Boca Raton, FL: CRC Press Inc; 1987:57-70.
45. Lanken PN, Minda M, Pietra GG, Fishman AP. Alveolar response to experimental Pneumocystis carinii pneumonia in the rat. Am J Pathol. 1980;99:561-588.
46. Yoneda K, Walzer P. Attachment of Pneumocystis carinii to type I alveolar cells studied by freeze-fracture electron microscopy. Infect Immun. 1983;40:812-815.
47. Long EG, Smith JS, Meier JL. Attachment of Pneumocystis carinii to rat pneumocytes. Lab Invest. 1986;54:609-615.
48. Pottratz ST, Paulsrud J, Smith JS, Martin WJ. Pneumocystis carinii attachment to cultured lung cells by Pneumocystis gp120, a fibronectin binding protein. J Clin Invest. 1991;88:403-407.
49. Limper AH, Standing JE, Hoffman OA, Castro M, Neese LW. Vitronectin binds to Pneumocystis carinii and mediates organism attachment to cultured lung epithelial cells. Infect Immun. 1993;61:4302-4309.
50. Fishman JA, Samia JA, Fuglestad J, Rose RM. The effects of extracellular matrix (ECM) proteins on the attachment of Pneumocystis carinii to lung cell lines in vitro. J Protozool. 1991;38:34S-37S.
51. Limper AH, Pottratz ST, Martin WJ. Modulation of Pneumocystis carinii adherence to cultured lung cells by a mannose-dependent mechanism. J Lab Clin Med. 1991;118:492-499.
52. Narasimhan S, Armstrong MY, Rhee K, Edman JC, Richards FF, Spicer E. Gene for an extracellular matrix receptor protein from Pneumocystis carinii. Proc Natl Acad Sci U S A. 1994;91:7440-7444.
53. Pottratz ST, Martin WJ. Role of fibronectin in Pneumocystis carinii attachment to cultured lung cells. J Clin Invest. 1990;85:351-356.
54. Furlong ST, Koziel H, Bartlett MS, McLaughlin GL, Shaw MM, Jack RM. Lipid transfer from human epithelial cells to Pneumocystis carinii in vitro. J Infect Dis. 1997;175:661-668.
55. Walzer PD, Powell RD, Yoneda K, Rutledge ME, Milder JE. Growth characteristics and pathogenesis of experimental Pneumocystis carinii pneumonia. Infect Immun. 1980;27:928-937.
56. Limper AH, Martin WJ. Pneumocystis carinii: inhibition of lung cell growth mediated by parasite attachment. J Clin Invest. 1990;85:391-396.
57. Breite WM, Bailey AM, Martin WJ. Pneumocystis carinii chymase is capable of altering lung epithelial cell permeability. Am Rev Respir Dis. 1993;147:A33.
58. Hidalgo HA, Helmke RJ, German VF, Mangos JA. Pneumocystis carinii induces an oxidative burst in alveolar macrophages. Infect Immun. 1992;60:1-7.
59. Koziel H, Li X, Armstrong MYK, Richards FF, Rose RM. Alveolar macrophages from human immunodeficiency virus-infected persons demonstrate impaired oxidative burst response to Pneumocystis carinii in vitro. Am J Respir Cell Mol Biol. 2000;23:452-459.
60. Beck JM, Preston AM, Wagner JG, et al. Interaction of rat Pneumocystis carinii and rat alveolar epithelial cells in vitro. Am J Physiol. 1998;275:L118-L125.
61. Atochina EN, Beers MF, Scanlon ST, Preston AM, Beck JM. P. carinii induces selective alterations in component expression and biophysical activity of lung surfactant. Am J Physiol Lung Cell Mol Physiol. 2000;278:L599-L609.
62. Tang X, Lasbury ME, Davidson DD, Bartlett MS, Smith JW, Lee CH. Down-regulation of GATA-2 transcription during Pneumocystis carinii infection. Infect Immun. 2000;68:4720-4724.
63. Lee CH, Lu JJ, Tang X, et al. Prevalence of various Pneumocystis carinii sp. f. hominis types in different geographical locations. J Euk Microbiol. 1996;43:37S.
64. Watts J, Chandler F. Evolving concepts of infection by Pneumocystis carinii. In: Rosen P, Fechner R, eds. Pathology Annual. Norwalk, Conn: Appleton & Lange; 1991:93-138.
65. Koziel H, Phelps DS, Fishman JA, Armstrong MYK, Richards FF, Rose RM. Surfactant protein-A reduces binding and phagocytosis of Pneumocystis carinii by human alveolar macrophages in vitro. Am J Respir Cell Mol Biol. 1998;18:834-843.
66. Fraser IP, Takahashi K, Koziel H, Fardin B, Harmsen A, Ezekowitz RAB. Pneumocystis carinii enhances the production of soluble mannose receptor by macrophages. Microbes Infect. 2000;2:1305-1310.
67. Frenkel J, Good J, Schultz J. Latent Pneumocystis infections of rats, relapse, and chemotherapy. Lab Invest. 1966;15:1559-1577.
68. Stokes DC, Gigliotti F, Rehg JE, Snellgrove RL, Hughes VCT. Experimental Pneumocystis carinii pneumonia in the ferret. Br J Exp Pathol. 1987;68:267-276.
69. Armstrong M, Smith A, Richards F. Pneumocystis carinii pneumonia in the rat model. J Protozool. 1991;38:136S-138S.
70. Settnes O, Genner J. Pneumocystis carinii in human lungs at autopsy. Scan J Infect Dis. 1986;18:489-496.
71. Millard PR, Heryet AR. Observations favouring Pneumocystis carinii pneumonia as a primary infection: a monoclonal antibody study on paraffin sections. J Pathol. 1988;154:365-370.
72. Wakefield AE, Pixley FJ, Banerji S, et al. Detection of Pneumocystis carinii with DNA amplification. Lancet. 1990;336:451-453.
73. Peters S, Wakefield A, Sinclair K, Millard P, Hopkins J. A search for Pneumocystis carinii in psot mortem lungs by DXA amplification. J Pathol. 1992;166:195-198.
74. Lee CH, Helweg-Larsen J, Lundgren B, et al. Update on Pneumocystis carinii f. sp. hominis typing based on nucleotide sequence variations in internal transcribed spacer regions of rRNA genes. J Clin Microbiol. 1998;36:734-741.
75. Keely SP, Stringer JR. Sequences of Pneumocystis carinii f. sp. hominis strains associated with recurrent pneumonia vary at multiple loci. J Clin Microbiol. 1997;35:2745-2747.
76. Latouche S, Ortona E, Mazars E, et al. Biodiversity of Pneumocystis carinii hominus: typing with different DNA regions. J Clin Microbiol. 1997;35:383-387.
77. Latouche S, Poirot JL, Bernard C, Roux P. Study of internal transcribed spacer and mitochondrial large subunit genes of Pneumocystis carinii hominis isolated by bronchoalveolar lavage from human immunodeficiency virus infected patients during one or several episodes of pneumonia. J Clin Microbiol. 1997;35:1687-1690.
78. Lu JJ, Bartlett MS, Shaw MM, et al. Typing of Pneumocystis carinii strains that infect humans based on nucleotide sequence variations of internal transcribed spacers of rRNA genes. J Clin Microbiol. 1994;32:2904-2912.
79. Lu JJ, Bartlett MS, Smith JW, Lee CH. Typing of Pneumocystis carinii strains with type-specific oligonucleotide probes derived from nucleotide sequences of internal transcribed spacers of rRNA genes. J Clin Microbiol. 1995;33:2973-2977.
80. Chen W, Gigliotti F, Harmsen AG. Latency is not an inevitable outcome of infection with Pneumocystis carinii. Infect Immun. 1993;61:5406-5409.
81. Masur H, Ognibene FP, Yarchoan R, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med. 1989;111:223-231.
82. Shellito JE, Suzara W, Blumenfeld W, Beck JM, Steger HJ, Ermak TH. A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes. J Clin Invest. 1990;85:1686-1693.
83. Beck JM, Warnock ML, Curtis JL, et al. Inflammatory responses to Pneumocystis carinii in mice selectively depleted of helper T lymphocytes. Am J Respir Cell Mol Biol. 1991;5:186-197.
84. Harmsen A, Stankiewicz M. Requirement for CD4+ cells in resistance to Pneumocystis carinii pneumonia in mice. J Exp Med. 1990;172:937-945.
85. Roths JB, Marshall JD, Allen RD, Carlson GA, Sidman CL. Spontaneous Pneumocystis carinii pneumonia in immunodeficient mutant seid mice. Am J Pathol. 1990;136:1173-1186.
86. Theus S, Andrews R, Steele P, Walzer P. Adoptive transfer of lymphocytes sensitized to the major surface glycoprotein of Pneumocystis carinii confers protection in the rat. J Clin Invest. 1995;95:2587-2593.
87. Ishimine T, Kawakami K, Nakamoto A, Saito A. Analysis of cellular response and gamma interferon synthesis in bronchoalveolar lavage fluid and lung homogenate of mice infected with Pneumocystis carinii. Microbiol Immunol. 1995;39:49-58.
88. Beck JM, Newbury R, Palmer B, Warnock M, Byrd P, Kaltreider H. Role of CD8+ lymphocytes in host defense against Pneumocystis carinii in mice. J Lab Clin Med. 1996;128:477-487.
89. Kolls JK, Habetz S, Shean MK, et al. IFN-gamma and CD8+ T-cells restore host defense against Pneumocystis carinii in mice depleted of CD4+ T-cells. J Immunol. 1999;162:2890-2894.
90. Lundgren B, Lundgren J, Mathiesen L, Nielsen J, Nielsen T, Kovacs J. Antibody responses to a major Pneumocystis carinii antigen in human immunodeficiency virus-infected patients with and without Pneumocystis carinii pneumonia. J Infect Dis. 1992;165:1151-1155.
91. Lundgren B, Lebech M, Lind K, Nielsen J, Lundgren J. Antibody response to a major human Pneumocystis carinii surface antigen in patients without evidence of immunosuppression and in patients with suspected atypical pneumonia. Eur J Clin Microbiol Infect Dis. 1993;12:105-109.
92. Marcotte H, Levesque D, Delaney K, et al. Pneumocystis carinii infection in transgenic B cell deficient mice. J Infect Dis. 1996;173:1034-1037.
93. Vassallo R, Thomas CF Jr, Vuk-Paklovic Z, Limper AH. Alveolar macrophage interactions with Pneumocystis carinii. J Lab Clin Med. 1999;133:535-540.
94. Limper AH, Hoyte JS, Standing JE. The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung. J Clin Invest. 1997;99:2110-2117.
95. Barton E, Campbell W. Pneumocystis carinii in lungs of rats treated with cortisone acetate. Am J Pathol. 1969;54:209-236.
96. Yoneda K, Walzer PD. The interaction of Pneumocystis carinii with host cells: an ultrastructural study. Infect Immun. 1980;29:692-703.
97. Harmsen AG, Chen W. Resolution of Pneumocystis carinii pneumonia in CD4+ lymphocyte-depleted mice given aerosols of heat-treated Escherichia coli. J Exp Med. 1992;176:881-886.
98. Masur H, Jones TC. The interaction in vitro of Pneumocystis carinii with macrophages and L-cells. J Exp Med. 1978;147:157-170.
99. von Behren LA, Pesanti EL. Uptake and degradation of Pneumocystis carinii by macrophages in vitro. Am Rev Respir Dis. 1978;118:1051-1059.
100. Ezekowitz RAB, Williams DJ, Koziel H, et al. Uptake of Pneumocystis carinii mediated by the macrophage mannose receptor. Nature. 1991;351:155-158.
101. Koziel H, Eichbaum Q, Kruskal BA, et al. Reduced binding and phagocytosis of Pneumocystis carinii by alveolar macrophages from persons infected with HIV-1 correlates with mannose receptor downregulation. J Clin Invest. 1998;102:1332-1334.
102. Taylor MB, Phillips M, Easmon CSF. Opsonophagocytosis of Pneumocystis carinii. J Med Microbiol. 1992;36:223-228.
103. Laursen AL, Obel N, Rungby J, Andersen PL. Phagocytosis and stimulation of the respiratory burst in neutrophils by Pneumocystis carinii. J Infect Dis. 1993;168;1466-1471.
104. Mason G, Hasimota C, Dickman P, Foutty L, Cobb C. Prognostic implications of bronchoalveolar lavage neutrophilia in patients with Pneumocystis carinii pneumonia and AIDS. Am Rev Respir Dis. 1989;139:1336-1342.
105. Smith RL, El-Sadir WM, Lewis ML. Correlation of bronchoalveolar lavage cell populations with clinical severity of Pneumocystis carinii pneumonia. Chest. 1988;92:60-64.
106. Weiss SJ. Tissue distruction by neutrophils. N Engl J Med. 1989;320:365-376.
107. Wright TW, Johnston CJ, Harmsen AG, Finkelstein JN. Analysis of cytokine mRNA profiles in the lungs of Pneumocystis carinii-infected mice. Infect Immun. 1997;17:491-500.
108. Garvy BA, Wiley JA, Gigliotti F, Harmsen AG. Protection against Pneumocystis carinii pneumonia by antibodies generated from either T helper 1 or T helper 2 responses. Infect Immun. 1997;65:5052-5056.
109. Chen W, Havell EA, Harmsen AG. Importance of endogenous tumor necrosis factor alpha and gamma interferon in host resistance against Pneumocystis carnii infection. Infect Immun. 1992;60:1279-1284.
110. Rudmann DG, Preston AM, Moore MW, Beck JM. Susceptibility to Pneumocystis carinii in mice is dependent on simultaneous deletion of IFN-gamma and type 1 and 2 TNF receptor genes. J Immunol. 1998;161:360.
111. Kolls J, Lei D, Vazquez C, et al. Exacerbation of murine Pneumocystis carinii infection by adenoviral-mediated gene transfer of TNF inhibitor. Am J Respir Cell Mol Biol. 1997;16:112-118.
112. Chen W, Havell EA, Moldawer LL, McIntyre KW, Chizzonite RA, Harmsen AG. Interleukin 1: an important mediator of host resistance against Pneumocystis carinii. J Exp Med. 1992;176:713-718.
113. Perenbroom R, Beckers P, van Der Meer J, et al. Pro-inflammatory cytokines in lung and blood during steroid-induced Pneumocystis carinii pneumonia in rats. J Leuk Biol. 1996;60:710-715.
114. Chen W, Havell E, Gigliotti F, Harmsen A. Interleukin-6 production in a murine model of Pneumocystis carinii pneumonia: relation to resistance and inflammatory response. Infec Immun. 1993;61:97-102.
115. Theus SA, Sullivan DW, Walzer PD, Smulian AG. Cellular responses to a 55-kilodalton recombinant Pneumocystis carinii antigen. Infect Immun. 1994;62:3479-3484.
116. Theus S, Andrews R, Linke M, Walzer P. Characterization of rat CD4 T cell clones specific for the major surface glycoprotein of Pneumocystis carinii. J Euk Microbiol. 1997;44:96-100.
117. Corsini E, Dykstra C, Craig W, Tidwell R, Rosenthal G. Pneumocystis carinii induction of tumor necrosis factor-alpha by alveolar macrophages: modulation by pentamidine isethionate. Immunol Lett. 1992;34:303-308.
118. Pesanti EL. Interaction of cytokines and alveolar cells with Pneumocystis carinii in vitro. J Infect Dis. 1991;163:611-616.
119. Taylor M, Easmon C. The neutrophil chemiluminescence response to Pneumocystis carinii is stimulated by GM-CSF and gamma interferon. FEMS Microbiol Immunol. 1991;4:41-44.
120. Garvy G, Ezekowitz A, Harmsen A. Role of gamma interferon in the host immune and inflammatory responses to Pneumocystis carinii infection. Infect Immun. 1997;65:373-379.
121. Beck JM, Liggitt HD, Burnette EN, Fuchs HJ, Shellito JE, Debs RJ. Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of gamma interferon. Infect Immun. 1991;59:3859-3862.
122. Pottratz S, Weir A. Gamma interferon inhibits Pneumocystis carinii attachment to lung cells by decreasing expression of lung cell-surface integrins. Eur J Clin Invest. 1997;27:17-22.
123. Mandujano J, D'Souza N, Nelson S, Summer W, Beckerman R, Shellito J. Granulocyte-macrophage colony stimulating factor and Pneumocystis carinii pneumonia in mice. Am J Respir Crit Care Med. 1995;151:1233-1238.
124. Paine RI, Preston AM, Wilcoxen S, et al. Granulocyte-macrophage colony stimulating factor in the innate response to Pneumocystis carinii pneumonia in mice. J Immunol. 2000;164:2602-2609.
125. Masur H, Lane C, Kovacs JA, Allegra CJ, Edman JC. Pneumocystis pneumonia: from bench to clinic. Ann Intern Med. 1989;111:813-826.
126. Armstrong MYK, Cushion MT. Animal models. In: Walzer PD, ed. Pneumocystis carinii Pneumonia. 2nd ed. New York, NY: Marcel Dekker Inc; 1993:182-187.
127. Walzer P. Experimental models of Pneumocystis carinii infections. In: Young L, ed. Pneumocystis carinii Pneumonia: Pathogenesis, Diagnosis, and Treatment. New York, NY: Marcel Dekker Inc; 1984:7-76.
128. Limper AH, Offord KP, Smith TF, Martin WJ II. Pneumocystis carinii pneumonia: differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis. 1989;140:1204-1209.
129. Sepkowitz KA, Brown AE, Telzak EE, Gottleb S, Armstrong D. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA. 1992;267:832-837.
130. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illnesses and prior corticosteroid therapy. Mayo Clin Proc. 1996;71:5-13.
131. Rifkind D, Starzl TE, Marchioro TL, et al. Transplantation pneumonia. N Engl J Med. 1964;322:161-165.
132. Slivka A, Wen PY, Shea WM, et al. Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors. Am J Med. 1993;94:216-219.
133. Walzer PD, LaBine M, Redington TJ, Cushion MT. Lymphocyte changes during chronic administration of and withdrawal from corticosteroids: relation to Pneumocystis carinii pneumonia. J Immunol. 1984;133:2502-2508.
134. Siminski J, Kidd P, Phillips GD, Collins C, Raghu G. Reversed helper/suppressor T-lymphocyte ratio in bronchoalveolar lavage fluid from patients with breast cancer and Pneumocystis carinii pneumonia. Am Rev Respir Dis. 1991;143:437-440.
135. Slade JD, Hepburn B. Prednisone-induced alterations of circulating human lymphocyte subsets. J Lab Clin Med. 1983;101:479-487.
136. Ten Berge RJM, Sauerwein HP, Young SL, et al. Administration of prednisolone in vivo affects the ratio of OKT4/OKT8 and the LDH-isoenzyme pattern of human T lymphocytes. Clin Immunol Immunopathol. 1984;30:91-103.
137. Mansharmani NG, Balachandran D, Vernovsky I, Garland R, Koziel H. Peripheral blood CD4+ T-lymphocyte counts during P. carinii pneumonia in immunocompromised patients without HIV infection. Chest. 2000;118:712-720.
138. Kovacs J, Hiemenz J, Macher A, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and other immunodeficiencies. Ann Intern Med. 1984;100:663-671.
139. Sepkowitz KA. Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis. 1993;17(suppl):S416-S422.
140. Hughes W. Pneumocystis carinii pneumonia. N Engl J Med. 1977;297:1381-1383.
141. Smith R, Ripps C, Lewis M. Elevated lactate dehydrogenase values in patients with Pneumocystis carinii pneumonia. Chest. 1988;93:987-992.
142. Doppman JL, Geelhoed GW, DeVita VT. Atypical radiologic features in Pneumocystis carinii pneumonia. Radiology. 1975;114:39-44.
143. Bigby T, Margolskee D, Curtis J, et al. The usefulness of induced sputum in the diagnosis of Pneumoncystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. Am Rev Respir Dis. 1986;133:515-518.
144. Stover DE, Zaman MB, Hajdu SI, Lange M, Gold J, Armstrong D. Bronchoalveolar lavage in the diagnosis of diffuse pulmonary infiltrates in the immunosuppressed host. Ann Intern Med. 1984;101:1-7.
145. Fraser J, Lilly C, Israel E, Hulme P, Hanaff P. Diagnostic yield of bronchoalveolar lavage and bronchoscopic lung biopsy for detection of Pneumocystis carinii. Mayo Clin Proc. 1996;71:1025-1029.
146. Walzer PD, Kim CK, Cushion MT. Pneumocystis carinii. In: Walzer PD, Genta RM, eds. Parasitic Infections in the Immunocompromised Host. New York, NY: Marcel Dekker Inc; 1989:83-178.
147. Baselski VS, Robison MK, Pifer LW, Woods DR. Rapid detection of Pneumocystis carinii in bronchoalveolar lavage samples by using Cellufluor staining. J Clin Microbiol. 1990;28:393-394.
148. Kovacs J, Ng V, Masur H, et al. Diagnosis of Pneumocystis carinii pneumonia: improved detection in sputum with use of monoclonal antibodies. N Engl J Med. 1988;318:589-593.
149. Torres J, Goldman M, Wheat LJ, et al. Diagnosis of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients with polymerase chain reaction: a blinded comparison to standard methods. Clin Infect Dis. 2000;30:141-145.
150. Weig M, Klinker H, Bogner BH, Meier A, Gross U. Usefulness of PCR for diagnosis of Pneumocystis carinii pneumonia in different patient groups. J Clin Microbiol. 1997;35:1445-1449.
151. Alvarez F, Bandi V, Stager C, Guntupalli KK. Detection of Pneumocystis carinii in tracheal aspirates of intubated patients using calcofluor-white (Fungi-Fluor) and immunofluorescence antibody (Genetic Systems) stains. Crit Care Med. 1997;25:948-952.
152. Evans R, Joss AW, Pennington TH, Ho-Yen DO. The use of a nested polymerase chain reaction for detecting Pneumocystis carinii from lung and blood in rat and human infection. J Med Microbiol. 1995;42:209-213.
153. Schindler MB, Cox PN. A simple method of bronchoalveolar lavage. Anaesth Intensive Care. 1994;22:66-68.
154. Hughes WT, Feldman S, Chaudhary SC, et al. Comparison of pentamidine isethionate and trimethoprim-sulfamelhoxazole in the treatment of Pneumocystis carinii pneumonia. J Pediatr. 1978;92:285-291.
155. Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1984;100:495-499.
156. Smith D, Davies S, Smithson J, Harding I, Gazzard BG. Enflornithine versus cotrimoxazole in the treatment of Pneumocystis carinii pneumonia in AIDS patients. AIDS. 1992;6:1489-1493.
157. USPHS/IDSA guidelines for the prevention of opportunistic infection in persons infected with human immunodeficiency virus: disease specific recommendations. Clin Infect Dis. 1997;25(suppl):S313-S335.
158. Lane BR, Ast JC, Hossler PA, et al. Dihydropteroate synthase polymorphisms in Pneumocystis carinii. J Infect Dis. 1997;175:482-485.
159. Ma L, Borio L, Masur H, Kovacs JA. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J Infect Dis. 1999;180:1969-1978.
160. Walker DJ, Wakefield AE, Dohn MN, et al. Sequence polymorphisms in the Pneumocystis carinii cytochrome b gene and their association with atovaquone prophylaxis failure. J Infect Dis. 1998;178:1767-1775.
161. Helweg-Larsen J, Benfield TL, Eugen-Olsen J, Lundgren JD, Lundgren B. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet. 1999;354:1347-1351.
162. Lundgren B, Jungstrom I, Rothman LP. Antibody responses to Pneumocystis carinii in hospital personnel with and without exposure to patients with P. carinii pneumonitis. J Euk Microbiol. 1996;43:10S.
163. Shelhamer JH, Ognibene FP, Macher AM, et al. Persistence of Pneumocystis carinii in lung tissue of acquired immunodeficiency syndrome patients treated for Pneumocystis carinii pneumonia. Am Rev Respir Dis. 1984;130:1161-1165.
164. Zaman MK, White DA. Serum lactate dehydrogenase levels and Pneumocystis carinii pneumonia. Am Rev Resp Dis. 1988;137:796-800.
165. National Institutes of Health-University of California expert panel for corticosteroids as adjunctive therapy for Pneumocystis pneumonia: consensus statement on the use of corticosteroid as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome. N Engl J Med. 1990;323:1500-1504.
166. Clement M, Edison R, Turner J, et al. Corticosteroids as adjunctive therapy in severe Pneumocystis carinii pneumonia: a prospective placebo-controlled trial. Am Rev Respir Dis. 1989;139:A250.
167. Gagnon S, Boota AM, Fischl MA, et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a double-blind, placebo-controlled trial. N Engl J Med. 1990;323:1444-1450.
168. Montaner J, Lawson L, Levitt N, Belzberg A, Schecter M, Ruedy J. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1990;113:14-20.
169. Bozzette SA, Sattler FR, Chiu J, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med. 1990;323:1451-1457.
170. Wright TW, Gigliotti F, Finkelstein JN, McBride JT, An CL, Harmsen AG. Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia. J Clin Invest. 1999;104:1307-1317.
171. Huang ZB, Eden E. Effect of corticosteroids on IL1-beta and TNF-alpha release by alveolar macrophages from patients with AIDS and Pneumocystis carinii pneumonia. Chest. 1993;104:751-755.
172. Waage A, Bakke A. Glucocorticoids suppress the production of TNF by LPS-stimulated human monocytes. Immunology. 1988;53:299-302.
173. Delclaux C, Zahar JR, Amraoui G, et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus-infected patients: retrospective study of 31 patients. Clin Infect Dis. 1999;29:670-672.
174. Chien S, Rawji M, Mintz S, Rachlis A, Chan CK. Changes in hospital admission pattern in patients with human immunodeficiency virus infection in the era of Pneumocystis carinii prophylaxis. Chest. 1992;102:1035-1039.
175. Wallace JM, Hansen NI, Lavange L, et al. Respiratory disease trends in the Pulmonary Complications of HIV Infection Study Cohort. Am J Respir Crit Care Med. 1997;155:72-80.
176. Michaels SH, Clark R, Kissinger P. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;339:405-406.
177. Centers for Disease Control and Prevention. Recommendations for prophylaxis against P. carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. Morbid Mortal Weekly Rep. 1992;41(RR-4):1-11.
178. Hughes WT, Kennedy W, et al. Safety and pharmacokinetics of 566C80, a hydroxynapthoquinone with anti-Pneumocystis carinii activity: a phase I study in HIV infected men. J Infect Dis. 1991;163:843-848.
179. Friedman Y, Franklin C, Rackow E, Weil MH. Improved survival in patients with AIDS, Pneumocystis carinii pneumonia, and severe respiratory failure. Chest. 1989;96:862-866.
180. Montaner J, Russell J, Lawson L, Ruedy J. Acute respiratory failure secondary to Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a potential role for systemic corticosteroids. Chest. 1989;95:881-884.
181. Wachter RM, Russi MB, Bloch DA, Hopewell PC, Luce JM. Pneumocystis carinii pneumonia and respiratory failure in AIDS: improved outcomes and increased use of intensive care units. Am Rev Respir Dis. 1991;143:251-256.
182. Franklin C, Friedman Y, Wong T, Hu TC. Improving long-term prognosis for survivors of mechanical ventilation in patients with AIDS with PCP and acute respiratory failure: five-year follow-up of intensive care unit discharges. Arch Intern Med. 1995;155:91-95.
183. Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1977;297:1419-1423.
184. Souza JP, Boeckh M, Gooley TA, Flowers MED, Crawford SW. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. Clin Infect Dis. 1999;29:1467-1471.
185. Sepkowitz KA, Brown AE, Armstrong D. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome: more patients, same risk. Arch Intern Med. 1995;155:1125-1128.
186. Hughes WT, Price RA, Kim HK, Coburn TP, Grigsby D, Feldman S. Pneumocystis carinii pneumonitis in children with malignancies. J Pediatr. 1973;82:404.
187. Hughes WT, Feldman S, Aur RJA, Verzosa MS, Hustu HO, Simone JV. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer. 1975;36:2004-2009.
188. Seigel SE, Nesbit ME, Baechner R, Sather H, Hammond GD. Pneumonia during therapy for childhood acute lymphoblastic leukemia. Am J Dis Child. 1980;134:28.
189. Cyklis R, Zielinska A. Pneumocystis carinii infection in children with acute leukemia and non-Hodgkin's malignant lymphoma. Pediatr Pol. 1983;58:337.
190. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Ann Intern Med. 1999;131:873-908.
191. Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. N Engl J Med. 1999;340:1301-1306.
192. Saukkonen K, Garland R, Koziel H. Aerosolized pentamidine as alternative primary prophylaxis against Pneumocystis carinii pneumonia in adult hepatic and renal transplant recipients. Chest. 1996;109:1250-1255.
193. Russian DA, Levine SJ. Pneumocystis carinii pneumonia in patients without HIV infection. Am J Med Sci. 2001;231:56-65.
194. Sepkowitz KA, Telzak EE, Gold JWM, et al. Pneumothorax in AIDS. Ann Intern Med. 1991;114:455-459.
195. Horner RD, Bennett CL, Rodriquez D, et al. Relationship between procedures and health insurance for critically ill patients with Pneumocystis carinii pneumonia. Am J Respir Crit Care Med. 1995;152:1435-1442.
196. Curtis JR, Greenberg DL, Hudson LD, Fisher LD, Krone MR, Collier AC. Changing use of intensive care for HIV-infected patients with Pneumocystis carinii pneumonia. Am J Respir Crit Care Med. 1994;150(5, pt 1):1305-1310.
197. Hawley PU, Ronco JJ, Guillemi SA, et al. Decreasing frequency but worsening mortality of acute respiratory failure secondary to AIDS-related Pneumocystis carinii pneumonia [see comments]. Chest. 1994;106:1456-1459.
198. Rosen MJ, Clayton K, Schneider RF, et al. Intensive care of patients with HIV infection: utilization, critical illnesses, and outcomes. Am J Respir Crit Care Med. 1997;155:67-71.
199. Sanyal SK, Avery TL, Hughes WT, Kumar MA, Harris KS. Management of severe respiratory insufficiency due to Pneumocystis carinii pneumonitis in immunosuppressed hosts: the role of continuous negative-pressure ventilation. Am Rev Respir Dis. 1977;116:223-231.
200. Nuesch R, Bellini C, Zimmerli W. Pneumocystis carinii pneumonia in human immunodeficiency virus (HIV)-positive and HIV-negative immunocompromised patients. Clin Infect Dis. 1999;29:1519-1523.
201. Evans TW. International concensus conferences in intensive care medicine: non-invasive positive pressure ventilation in acute respiratory failure. Intensive Care Med. 2001;27:166-178.
202. Bedros JP, Dumoulin JL, Gachot B, et al. Pneumocystis carinii pneumonia requiring intensive care management. Crit Care Med. 1999;27:1109-1115.
203. Linden V, Karlen J, Olsson M, et al. Successful extracorporeal membrane oxygenation in four children with malignant disease and severe Pneumocystis carinii pneumonia. Med Pediatr Oncol. 1999;32:25-31.
204. Nhieu JT, Vojtek AM, Bernaudin JF, Escudier E, Fleury-Feith J. Pulmonary alveolar proteinosis associated with Pneumocystis carinii: ultrastructural identification in bronchoalveolar lavage in AIDS and immunocompromised non-AIDS patients. Chest. 1990;98:801-805.
205. Wright TW, Johnston CJ, Harmsen AG, Finkelstein JN. Chemokine gene expression during Pneumocystis carinii-driven pulmonary inflammation. Infect Immun. 1999;67:3452.
206. Dohn MN, Baughman RP, Vigdorth EM, Frame DL. Equal survival rates for first, second, and third episodes of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Arch Intern Med. 1992;152:2465-2470.
207. Burke BA, Good RA. Pneumocystis carinii infection. Medicine. 1973;52:23-51.
208. Agarwal J, Agarwal G, Ayyagari A, Kar DK, Mishra SK, Bhatia E. Isolated Pneumocystis carinii infection of adrenal glands causing Addison's disease in non-immunocompromised adult. Endocr Pathol. 2001;12:87-91.